Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 1.02
BCRX's Cash-to-Debt is ranked lower than
81% of the 847 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. BCRX: 1.02 )
Ranked among companies with meaningful Cash-to-Debt only.
BCRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.02  Med: No Debt Max: No Debt
Current: 1.02
Equity-to-Asset 0.02
BCRX's Equity-to-Asset is ranked lower than
90% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: 0.65 vs. BCRX: 0.02 )
Ranked among companies with meaningful Equity-to-Asset only.
BCRX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.02  Med: 0.59 Max: 0.97
Current: 0.02
-0.02
0.97
Piotroski F-Score: 2
Altman Z-Score: -5.69
Beneish M-Score: -2.07
WACC vs ROIC
24.45%
-390.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -184.45
BCRX's Operating Margin % is ranked lower than
58% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -92.73 vs. BCRX: -184.45 )
Ranked among companies with meaningful Operating Margin % only.
BCRX' s Operating Margin % Range Over the Past 10 Years
Min: -336.35  Med: -105.32 Max: -18.42
Current: -184.45
-336.35
-18.42
Net Margin % -209.25
BCRX's Net Margin % is ranked lower than
60% of the 648 Companies
in the Global Biotechnology industry.

( Industry Median: -81.52 vs. BCRX: -209.25 )
Ranked among companies with meaningful Net Margin % only.
BCRX' s Net Margin % Range Over the Past 10 Years
Min: -332.08  Med: -118.9 Max: -18.03
Current: -209.25
-332.08
-18.03
ROE % -291.83
BCRX's ROE % is ranked lower than
94% of the 756 Companies
in the Global Biotechnology industry.

( Industry Median: -38.58 vs. BCRX: -291.83 )
Ranked among companies with meaningful ROE % only.
BCRX' s ROE % Range Over the Past 10 Years
Min: -544.61  Med: -69.75 Max: -20.28
Current: -291.83
-544.61
-20.28
ROA % -56.41
BCRX's ROA % is ranked lower than
69% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -33.01 vs. BCRX: -56.41 )
Ranked among companies with meaningful ROA % only.
BCRX' s ROA % Range Over the Past 10 Years
Min: -59.43  Med: -40.93 Max: -11.86
Current: -56.41
-59.43
-11.86
ROC (Joel Greenblatt) % -557.48
BCRX's ROC (Joel Greenblatt) % is ranked lower than
51% of the 811 Companies
in the Global Biotechnology industry.

( Industry Median: -496.85 vs. BCRX: -557.48 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BCRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15669.01  Med: -948.36 Max: -202.66
Current: -557.48
-15669.01
-202.66
3-Year Revenue Growth Rate 4.50
BCRX's 3-Year Revenue Growth Rate is ranked higher than
50% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.60 vs. BCRX: 4.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BCRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -70.7  Med: -13.6 Max: 528
Current: 4.5
-70.7
528
3-Year EBITDA Growth Rate 13.00
BCRX's 3-Year EBITDA Growth Rate is ranked higher than
63% of the 506 Companies
in the Global Biotechnology industry.

( Industry Median: 1.70 vs. BCRX: 13.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BCRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -41.9  Med: -1.3 Max: 63.7
Current: 13
-41.9
63.7
3-Year EPS without NRI Growth Rate 10.90
BCRX's 3-Year EPS without NRI Growth Rate is ranked higher than
64% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: -2.80 vs. BCRX: 10.90 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BCRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -38.4  Med: -3.8 Max: 52.9
Current: 10.9
-38.4
52.9
» BCRX's 10-Y Financials

Financials (Next Earnings Date: 2017-05-27 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

BCRX Guru Trades in Q1 2016

John Paulson 263,100 sh (New)
Chuck Royce 160,000 sh (New)
Paul Tudor Jones 125,588 sh (+1022.83%)
Jim Simons 292,221 sh (+104.49%)
Joel Greenblatt Sold Out
» More
Q2 2016

BCRX Guru Trades in Q2 2016

John Paulson 263,100 sh (unchged)
Chuck Royce 160,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 16,687 sh (-86.71%)
» More
Q3 2016

BCRX Guru Trades in Q3 2016

John Paulson 363,100 sh (+38.01%)
Chuck Royce 160,000 sh (unchged)
Paul Tudor Jones 11,137 sh (-33.26%)
» More
Q4 2016

BCRX Guru Trades in Q4 2016

Jim Simons 49,903 sh (New)
John Paulson 350,000 sh (unchged)
Paul Tudor Jones Sold Out
Chuck Royce 144,000 sh (-10.00%)
John Paulson 52,600 sh (-85.51%)
» More
» Details

Insider Trades

Latest Guru Trades with BCRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:LJPC, NAS:ITCI, NAS:MGNX, NAS:ACIU, NAS:VSAR, OTCPK:IPHYF, NAS:VNDA, NAS:NLNK, NAS:ANIK, NAS:NDRM, NAS:RETA, NAS:KERX, NAS:IMMU, NAS:WVE, OTCPK:PHMMF, OTCPK:MEOBF, NAS:JNCE, NAS:ARDX, NAS:INSY, NAS:AMRI » details
Traded in other countries:BO1.Germany,
Biocryst Pharmaceuticals Inc is a biotechnology company. The Company designs, optimizes and develops novel small molecule drugs that block key enzymes involved in the pathogenesis of diseases.

Biocryst Pharmaceuticals is a biotechnology company involved mainly in the research and development of novel small-molecule drugs, with the aim of blocking key enzymes involved in infectious and inflammatory diseases. Biocryst's research is based on multiple scientific disciplines like biology, computer modelling, and medical chemistry. Its products and candidates target the following therapeutic areas: acute uncomplicated influenza; uncomplicated seasonal influenza; hereditary angioedema; filoviruses, including the Ebola and Marburg viruses; and oncology.

Ratios

vs
industry
vs
history
PB Ratio 405.26
BCRX's PB Ratio is ranked lower than
100% of the 975 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. BCRX: 405.26 )
Ranked among companies with meaningful PB Ratio only.
BCRX' s PB Ratio Range Over the Past 10 Years
Min: 1.05  Med: 8.8 Max: 438.08
Current: 405.26
1.05
438.08
PS Ratio 23.85
BCRX's PS Ratio is ranked lower than
62% of the 774 Companies
in the Global Biotechnology industry.

( Industry Median: 13.23 vs. BCRX: 23.85 )
Ranked among companies with meaningful PS Ratio only.
BCRX' s PS Ratio Range Over the Past 10 Years
Min: 0.66  Med: 7 Max: 614.52
Current: 23.85
0.66
614.52
Current Ratio 1.23
BCRX's Current Ratio is ranked lower than
85% of the 821 Companies
in the Global Biotechnology industry.

( Industry Median: 4.03 vs. BCRX: 1.23 )
Ranked among companies with meaningful Current Ratio only.
BCRX' s Current Ratio Range Over the Past 10 Years
Min: 1.02  Med: 4.33 Max: 28.59
Current: 1.23
1.02
28.59
Quick Ratio 1.22
BCRX's Quick Ratio is ranked lower than
81% of the 820 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. BCRX: 1.22 )
Ranked among companies with meaningful Quick Ratio only.
BCRX' s Quick Ratio Range Over the Past 10 Years
Min: 1  Med: 4.33 Max: 28.59
Current: 1.22
1
28.59
Days Inventory 222.92
BCRX's Days Inventory is ranked lower than
74% of the 375 Companies
in the Global Biotechnology industry.

( Industry Median: 132.21 vs. BCRX: 222.92 )
Ranked among companies with meaningful Days Inventory only.
BCRX' s Days Inventory Range Over the Past 10 Years
Min: 142.81  Med: 307.94 Max: 15234.51
Current: 222.92
142.81
15234.51
Days Sales Outstanding 121.44
BCRX's Days Sales Outstanding is ranked lower than
78% of the 524 Companies
in the Global Biotechnology industry.

( Industry Median: 59.75 vs. BCRX: 121.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
BCRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.54  Med: 131.08 Max: 200.48
Current: 121.44
44.54
200.48
Days Payable 577.32
BCRX's Days Payable is ranked higher than
95% of the 341 Companies
in the Global Biotechnology industry.

( Industry Median: 59.13 vs. BCRX: 577.32 )
Ranked among companies with meaningful Days Payable only.
BCRX' s Days Payable Range Over the Past 10 Years
Min: 577.32  Med: 8523.65 Max: 34806.57
Current: 577.32
577.32
34806.57

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -7.70
BCRX's 3-Year Average Share Buyback Ratio is ranked higher than
62% of the 558 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. BCRX: -7.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BCRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20.4  Med: -8.3 Max: -0.6
Current: -7.7
-20.4
-0.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 425.50
BCRX's Price-to-Tangible-Book is ranked lower than
100% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.44 vs. BCRX: 425.50 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BCRX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.42  Med: 4.08 Max: 460
Current: 425.5
0.42
460
Price-to-Median-PS-Value 3.40
BCRX's Price-to-Median-PS-Value is ranked lower than
89% of the 673 Companies
in the Global Biotechnology industry.

( Industry Median: 1.02 vs. BCRX: 3.40 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BCRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.13  Med: 2.41 Max: 418.75
Current: 3.4
0.13
418.75
Earnings Yield (Greenblatt) % -7.74
BCRX's Earnings Yield (Greenblatt) % is ranked higher than
57% of the 1109 Companies
in the Global Biotechnology industry.

( Industry Median: -10.11 vs. BCRX: -7.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BCRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -7.95  Med: 487.1 Max: 1563.9
Current: -7.74
-7.95
1563.9

More Statistics

Revenue (TTM) (Mil) $26.35
EPS (TTM) $ -0.75
Beta3.00
Short Percentage of Float20.50%
52-Week Range $2.48 - 9.25
Shares Outstanding (Mil)74.02

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 33 33 13
EPS ($) -0.75 -0.64 -1.05
EPS without NRI ($) -0.75 -0.64 -1.05
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for BCRX

Headlines

Articles On GuruFocus.com
A Trump Presidency May Be Good for Biotech Dec 16 2016 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 15 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-K/A) Jan 19 2011 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 08 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 2,500 Shares Aug 06 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares Jun 04 2010 
BioCryst Pharmaceuticals Inc. Reports Operating Results (10-Q) May 07 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 1,250 Shares May 05 2010 
BioCryst Pharmaceuticals Inc. (BCRX) SR VP & CFO Stuart Grant sells 38,553 Shares Apr 30 2010 

More From Other Websites
Wait for the Pullback on BioCryst Pharmaceuticals Mar 20 2017
Don't Let Offerings Blindside Your Thesis Mar 19 2017
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement,... Mar 17 2017
BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue? Mar 15 2017
BIOCRYST PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 15 2017
It’s time to vaccinate your investments against a deadly bird flu Mar 14 2017
BioCryst Pharmaceuticals Prices Public Offering of Common Stock Mar 09 2017
Biotech Premarket Movers: Spectrum, BioCryst, Curis Mar 09 2017
BioCryst Pharmaceuticals Commences Public Offering of Common Stock Mar 08 2017
Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session Mar 08 2017
BioCryst Pharmaceuticals, Inc. :BCRX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
BIOCRYST PHARMACEUTICALS INC Financials Mar 03 2017
Biotech's Outlook Strengthens After President Trump's Speech: Today's Reports on Sarepta... Mar 03 2017
BioCryst Pharmaceuticals, Inc. (BCRX): A Discount Entry? Mar 01 2017
BioCryst 4Q Net 6 Cents a Share Beats Street Feb 28 2017
Edited Transcript of BCRX earnings conference call or presentation 27-Feb-17 2:00pm GMT Feb 27 2017
BioCryst Pill Prevents Swelling Attacks but Shares Fall on Competitive Concerns Feb 27 2017
Biotech Premarket Movers: BioCryst, Sangamo, Cempra Feb 27 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)